Susana Haydée Belli is an Endocrinologist and Head of the Department of Endocrinology at Instituto Alexander Fleming, Buenos Aires, Argentina since 2004. She is a founding member of the Argentine Group of Neuroendocrine Tumors (ARGENTUM), which started in 2005, member of the Argentinian Endocrine Society and chief of the group for the study of adrenal diseases. Susana is also a member of the Advisory Board of the European Society of Neuroendocrine Tumors (ENETS) since 2018 and is currently involved in the development of the Clinical Practice Guidelines in GEP-NET in the National Academy of Medicine, Argentina. She has authored over 50 papers on endocrinology diseases and is an active speaker in national and international endocrinology events.

Dr. Emily Bergsland is a Professor of Medicine and holds the Ernest Rosenbaum, MD Endowed Chair of Medical Oncology. She received her medical degree from the University of Minnesota and completed her internship, residency, and chief residency in internal medicine at University of California, San Francisco (UCSF). She subsequently completed fellowships in Medical Oncology and Molecular Medicine before joining the UCSF faculty in 1998. A gastrointestinal oncologist, Dr. Bergsland is the Director of the UCSF Center for Neuroendocrine Tumors and leads a multi-disciplinary clinical and translational research team focused on neuroendocrine tumors (NETs). At a national level, Dr. Bergsland is Chair of the NET Task Force for the National Cancer Institute, Co-Chair of the North American Neuroendocrine Tumor Society (NANETS), and a member of the NCCN NET guidelines panel. She is also the principal investigator for a national study of pazopanib v placebo in patients with carcinoid tumors performed by the ALLIANCE for Clinical Trials and funded by the National Cancer Institute.

Professor Jie Chen is Deputy Director of the Department of Gastroenterology, the First Affiliated Hospital，Sun Yat-Sen University, Guangdong, China. Her main area of interest is digestive neuroendocrine tumors. As one of the pioneer experts for NETs in China, she focusses her attention on clinical and translational research in GEP-NETs. She founded the first Multidisciplinary Care Team for NETs in China in 2011 as well as the Chinese Study Group for Neuroendocrine Tumors (CSNET) in 2015. She is currently the Chair of CSNET. Her major areas of research interest are the therapeutic strategies of NETs and the development of biomarkers of diagnostic or therapeutic interest in NETs. She has published high-quality peer-reviewed papers in the NET field over the past nine years. She was an Advisory Board Members at European Neuroendocrine Tumor Society (ENETS) from 2015 to 2018. She joined the editorial board of Neuroendocrinology in 2019.

Professor Massimo Falconi, MD is currently Full Professor of Surgery and Chairman of the Pancreatic Unit at the University Vita e Salute, San Raffaele Hospital IRCCS, in Milan, Italy. In addition to his new osition as the 2016 – 2018 Chairman of ENETS, Prof. Falconi is currently also on the executive committee of IAP. Furthermore, he is a member of the medical society EPC and EAHPBA.

He serves as Associate Editor for the section of the pancreas and neuroendocrine tumors for Digestive and Liver Disease, official journal of the Italian and French Gastroenterological societies. He is also editorial member of the following journals: World Journal of Gastroenterology, subject Area Editor of The International Journal of Biological Markers and of International Journal of Endocrine Oncology. He has an impact factor calculated on the basis of JCR 2013 of more than 1,400 and his h index on Scopus is 58.
He has written almost 300 peer-reviewed articles and currently reviews articles for the following publications: Annals of Oncology, British Journal of Surgery, Cochrane, Gut, Lancet, Neuroendocrinology, Nutrition, Pancreas, Pancreatology, Journal of Endocrinological Investigation (JEI), Journal Of the Pancreas (JOP), Surgery, Annals of Surgery.
Prof. Falconi studied medicine at the University of Verona, specializing in general surgery, gastroenterology and endoscopy. He has participated in international medical research projects in such diverse places as Germany, Spain, Ecuador and Japan.

Rod is a Professorial Fellow of the University of Melbourne, Director of Molecular Imaging and Therapeutic Nuclear Medicine at the Peter MacCallum Cancer Centre in Melbourne. His group has a strong focus on translational research. He first established peptide receptor radionuclide therapy in Australia in 1996. The Neuroendocrine Tumour Service, which he co-chairs, was recently certified as ENETS Center of Excellence. He has published more than 450 peer-reviewed articles. He is Editor-in-Chief of Cancer Imaging and on six other editorial boards, including Endocrine-related Cancer. He received a National Health and Medical Research Council Program Grant in 2013; in 2015, he received a NHMRC Practitioner Fellowship and was inducted as a Fellow of the Australian Academy of Health and Medical Science.

Dr. Howe is Director of the Division of Surgical Oncology and Endocrine Surgery, Co-Director of the Neuroendocrine Cancer Clinic and a Professor of Surgery at the University of Iowa Carver College of Medicine. He did his General Surgery residency at Washington University and Surgical Oncology fellowship at Memorial Sloan-Kettering Cancer Center. Past research activities included studies to identify the pre-disposing genes for MEN2A and Juvenile Polyposis. His current research efforts are directed towards understanding the genetics of neuroendocrine tumors, specifically looking for pre-disposing genes as well as using gene expression profiles to make diagnoses and identify new therapeutic targets. His clinical focus is on the surgical management of small bowel and pancreatic neuroendocrine tumors and their metastases.

Dr. B.A. Krishna is the Director of Nuclear Medicine and PET imaging at Lilavati Hospital and Research Centre, Mumbai, India. He has more than 40 years’ experience in nuclear imaging & thyroid cancer management and 14 years’ experience in imaging and therapy of neuroendocrine tumors.   In 2008, he set up the 177Lu-DOTA scan and therapy facilities using indigenously produced isotopes. His group presented the first data on using 177-Lu-DOTA scan as dosimetry scan prior to PRRT. In 2015, he has established NET center in Mumbai where multi-disciplinary NET clinics & PRRT facilities have been instituted. He hosted the 5th APNETS conference in 2017 in Mumbai. At this conference, i-NET (Indian NeuroEndocrine Tumor Group) was inaugurated. He is the co-coordinator of this group and has conducted three NET seminars in different parts of the country to propagate NET as a speciality in India.

Simone Leyden is the Co-Founder and CEO of the Unicorn Foundation Australia, which was established in 2009. In her role as CEO, Simone advocates for greater access to treatments and diagnostics, raises funds for the NET Nurse Support Service and research, produces resources and education materials about neuroendocrine tumors (NETs), and raises awareness about NET cancers within the medical community and public. Simone is an active member of many associations, including the current President and Communications Chair of the International Neuroendocrine Cancer Alliance (INCA), and has successfully convened NET-related medical conferences in Australia including the 4th World Theranostics Congress (2016), International Symposium on Pheochromocytomas and Paragangliomas (2017) and Asia Pacific Neuroendocrine Tumour Society (2018). Simone is passionate about improving the lives and outcomes of NET and rare-cancer patients around the world and bringing the patient voice to the forefront of research.

Toshihiko Masui is Associate Professor in the Division of Hepatobiliary, Pancreatic Surgery and Transplantation in the Department of Surgery at Kyoto University, Kyoto, Japan. He is also the Secretary General for the Japan Neuroendocrine Tumor Society (JNETS).

Professor Masui’s general interests include the mechanisms of malignancy difference within NENs in basic science and the epidemiology of NEN in Japan. His current project elucidates how surrounding tissue supports the growth of NEN and clarifies the present status of NEN patients in Japan by using national registry.

Professor Masui was bestowed the Pancreatic Disease Research Encouragement Award in 2016.

Dermot O’Toole is Professor in Gastroenterology and Clinical Medicine at Trinity College Dublin (TCD, The University of Dublin) and Consultant Gastroenterologist in St James’s and St Vincent’s University Hospitals Dublin. He graduated from TCD and has postgraduate degrees from TCD and the Universities of Paris and Angers. His major research interest is in gastrointestinal cancer biology especially in neuroendocrine tumour (NET)-related diseases and early GI neoplasia (Barrett’s oesophagus, gastric and colorectal cancers). Professor O’Toole is Clinical Lead for the national NET group. He has served on the executive committee of the European Neuroendocrine Tumours Society (ENETS) and is current President of ENETS helping to develop guidelines papers and standards of care initiatives in the field of NET. He is past Chair of the ENETS-driven European Centre of Excellence program. He has been involved in many national and international research activities in GI oncology and is a member of several professional bodies in Europe and North America serving as advisor on national health care projects/initiatives and on patient advocacy groups.

Marianne Pavel is a Senior Physician and Chair of Endocrinology at the Friedrich-Alexander University of Erlangen, Germany, where she is heading the NET center, too. Her major focus in medicine for the last 20 years is neuroendocrine tumors. She is first author of the 2012 and the updated 2016 “ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary”. Board certified as a specialist in internal medicine in 2000, and endocrinology/diabetes in 2001, she was appointed as Vice Head of the Division of Endocrinology and Metabolism at the Friedrich-Alexander University Erlangen in 2001. She took a position as an Assistant Director at the Charité University Hospital in Berlin in 2007 and was conferred a Professorship for NET Disease at the Charité University in 2010. She has conducted numerous clinical trials in the field of NET and supports the activities of ENETS since 2005. In 2009, under her guidance, the NET Center at the Charité University was certified as one of the first ENETS Centers of Excellence. She is a member of the ENETS Executive Committee since April 2014 and has been elected as Chair of ENETS after 2020.

Professor Aurel Perren, MD, is a Professor of Pathology at the University Bern. In addition to currently serving as ENETS Scientific Secretary, Professor Perren is also regularly involved in ENETS activities and task-force issues. He enriches multi-disciplinary discussions by bringing pathological and genetic viewpoints to the table. He has published in numerous scientific journals and is member of the editorial boards of Endocrine Pathology, Pathobiology, Virchows Archives and Endocrine-related Cancer.  His research focuses on the histopathological and genetic analysis of familial and sporadic NET with a special interest in pancreatic NET. He was involved in the WHO classification of endocrine tumors 2004 and has been involved since the first Frascati meeting in 2005.

Dr. Singh is the Co-Head of the Susan Leslie Clinic for Neuroendocrine Cancers at the Odette Cancer Center in Toronto, Ontario – the largest of its kind in Canada.  He specialises in improving clinical outcomes as well as quality improvement in the care of patients with neuroendocrine cancers.  He is the Co-Chair of the Commonwealth Neuroendocrine Tumour research collaboration as well as the North American Neuroendocrine Tumor Society Annual Meeting Co-Chair. He has published extensively on NETs and holds numerous peer-reviewed grants to improve the care of patients with NETs. He has been invited extensively around the world to speak on improving disease outcomes in NETs. Dr. Singh is an Associate Scientist at the Institute for Clinical Evaluative Sciences in Toronto, Canada, as well as the Provincial Head of the Person Centered Care portfolio at Cancer Care Ontario.

Bertram Wiedenmann is Professor of Internal Medicine and Gastroenterology and since 1997, is Head of the Department of Gastroenterology and Hepatology at Charité University Hospital in Berlin, Germany. He is a member of the Charité Supervisory Board since 2017. Following his discovery of synaptophysin (1985), his scientific interests focused on translational research in gastrointestinal oncology, specifically NET of the gastroenteropancreatic system. He was a Co-Founder of ENETS in 2004 and has also initiated the ENETS Centers of Excellence and developed the CoE Excellence Academy Fellowship Programme. He served from 2004 to 2006 as ENETS first Chairman and is its Treasurer since 2008. He is a member of several international and national societies. He is an Assistant Editor of the official ENETS journal, Neuroendocrinology, and member of several editorial boards. He has published in numerous leading scientific peer-reviewed journals. He has been Congress President 2016 of the German Society of Gastroenterology (DGVS), AGA Institute representative and Chair for the 2016-2017 Program Committee GI ASCO, Member of the Steering Committee GI ASCO 2018-2019.

Professor Hong Zhao, M.D., works in the Department of Hepatobiliary Surgery, Cancer Hospital, Chinese Academy of Medical Science & Peking Union Medical College in China. He is also the Secretary General of Chinese Neuroendocrine Tumor Society (CNETS). His general scientific interests include gastroenteropancreatic neuroendocrine Tumors, hepatocellular carcinomas colorectal cancer liver metastases and abdominal surgery.

His current projects comprise genome sequencing analysis of gastric NEC and molecular mechanism research on colorectal cancer liver metastasis.

Professor Zhao has received the following honours:

• 2015 Top 10 outstanding young physicians of the capital of China
• 2014 Science and Technology Progress Award of Beijing City
• 2013 HUAXIA Medical Science Prize